



EP07.63: Outcomes of Perioperative Immune Checkpoint Inhibitors and Chemoradiotherapy in Stage II–III Non–Small Cell Lung Cancer

Takashi Inoue¹, Atsuhiro Takahashi¹, Kouhei Sugamo¹, Kenta Hasumi¹, Kenta Nakahashi¹, Aya Nomura¹, Osamu Araki¹, Takahiroya Nakajima¹, Sumiko Maeda¹, Emi Ueno¹, Naomi Ebihara¹, Fumiya Fukushima², Masayuki Chida¹

¹Dokkyo Medical University, ²Nasu Redcross Hospital **Correspondence:** t-inoue@dokkyomed.ac.jp



INTRODUCTION


- Immune checkpoint inhibitor (ICI) administration has emerged as standard perioperative treatment for non–small cell lung cancer (NSCLC).
- At our institution, preoperative chemoradiotherapy (CRT) had previously been administered to patients with N2-positive NSCLC.
- This study evaluated the clinical outcomes of perioperative ICI-based therapy compared with preoperative CRT.

METHODS

- The CRT group was comprised of 22 patients who underwent perioperative ICI therapy between January 2011 and December 2018, and the ICI group included 39 patients who underwent preoperative CRT between January 2022 and December 2025.
- Follow-up examinations for patient in both groups were performed in December 2025.
- Recurrence and survival outcomes were retrospectively analyzed, and subgroup analyses were performed according to the perioperative treatment strategy.



DISCUSSION AND CONCLUSION

- In both in the CRT and ICI groups, patients without postoperative therapy had shorter disease-free survival (DFS) than those who received it.
- In the ICI group, overall survival (OS) did not differ between patients with and without postoperative therapy.
- This discrepancy may be partly explained by differences in post-recurrence treatment strategies.
- Among patients with NSCLC, perioperative ICI therapy may offer a prognostic benefit compared with preoperative CRT alone.
- Completion of multimodal treatment, including postoperative adjuvant therapy, was associated with improved outcomes in both treatment strategies.
- In contrast, neoadjuvant ICI plus chemotherapy alone may be associated with a higher risk of recurrence, highlighting the importance of comprehensive perioperative management.



RESULTS

	ICI therapy (n=39)	CRT (n=22)
Average age, years	69.3 (43–78)	66.4 (46–80)
Sex	Male, 35	Male, 21
	Female, 4	Female, 1
Pathological type	Adeno, 20	Adeno, 9
	Squamous, 17	Squamous, 9
	LCNEC, 1	LCNEC, 4
	Pleomorphic, 1	—
TNM Stage (9th)	IIA, 2	—
	IIB, 9	—
	IIIA, 26	IIIA, 19
	IIIB, 2	IIIB, 3



	ICI Therapy (n=39)	CRT (n=22)
Treatment	Preop Nivo+Chemo (CM816), 12	CDDP+VNR, 20
	Postop Chemo→Atezo (IM010), 22	CBDCA+VNR, 3
	Preop Pembro+Chemo →Postop Pembro (KN671), 6	
Follow-up, days	505	1143
	Overlapping cases included	Overlapping cases included

